The medications most likely to cause tardive dyskinesia (TD) are drugs that block dopamine receptors in the brain, particularly antipsychotics. First-generation antipsychotics carry the highest risk, with about 25% of long-term users developing the condition. But several non-psychiatric medications, especially certain anti-nausea drugs, can also trigger it.
First-Generation (Typical) Antipsychotics
These older antipsychotics are the most common cause of TD. They bind tightly to dopamine receptors, and that strong blockade is what makes them especially likely to produce involuntary movements over time. The pooled prevalence of TD among people taking first-generation antipsychotics is roughly 25.3%, meaning about one in four long-term users will develop symptoms.
The most frequently implicated drugs in this class include:
- Haloperidol (Haldol), a widely prescribed antipsychotic shown to promote involuntary movements partly through triggering inflammatory changes in the brain
- Chlorpromazine (Thorazine), one of the earliest antipsychotics and consistently associated with high rates of TD
- Fluphenazine (Prolixin)
- Perphenazine (Trilafon)
These medications are still used for conditions like schizophrenia, bipolar disorder, and severe agitation. If you take one, TD typically develops after at least three months of use, though in older adults it can appear after just one month.
Second-Generation (Atypical) Antipsychotics
Newer antipsychotics carry a lower but real risk. The overall annualized incidence of TD across all second-generation antipsychotics is about 2.6%, compared to significantly higher rates with older drugs. That reduced risk is one reason these medications have largely replaced the first-generation options, but “lower risk” does not mean “no risk.”
Some specific second-generation antipsychotics have been linked to TD more than others. Risperidone, aripiprazole (Abilify), and amisulpride have all been reported to trigger TD in certain patients. Olanzapine (Zyprexa) appears to carry a relatively low incidence of about 2.7%. Quetiapine (Seroquel) shows a similarly low rate of around 2.8%, though in head-to-head comparisons its advantage over older antipsychotics was smaller than expected.
Clozapine (Clozaril) occupies a unique position. While its raw incidence numbers look higher in some studies (around 4-8%), it is actually considered the safest option for people who already have TD and still need an antipsychotic. Research suggests clozapine can reverse TD symptoms in some cases, and drugs with similar brain activity, like quetiapine and olanzapine, have also shown some ability to improve existing TD.
Anti-Nausea Medications
This is the category that catches many people off guard. Several common drugs prescribed for nausea, vomiting, acid reflux, and gastroparesis block dopamine in the same way antipsychotics do, and they carry real TD risk.
Metoclopramide (Reglan) is the most notable. It is prescribed for gastroparesis and gastroesophageal reflux, and in 2009 the FDA required a black box warning on its label specifically about tardive dyskinesia. The warning states that chronic use beyond 12 weeks should be avoided except in rare cases where the benefit clearly outweighs the risk. Despite this, many patients end up taking it for longer periods without being informed of the danger.
Prochlorperazine (Compazine), used for nausea and vertigo, has shown an even higher frequency of TD than metoclopramide in some clinical trials. Promethazine (Phenergan), another common anti-nausea drug, also blocks dopamine and carries TD risk. All three are widely used in emergency rooms for migraines and stomach illness, which means even short courses could begin a process that leads to problems with repeated exposure.
Why These Drugs Cause Involuntary Movements
All of the medications above share one thing in common: they block dopamine receptors, particularly a type called D2 receptors, in the part of the brain that controls movement. When these receptors are blocked for weeks or months, the brain tries to compensate by becoming more sensitive to dopamine. Over time, the receptors essentially overreact to even small amounts of dopamine that get through. This supersensitivity produces the uncontrolled, repetitive movements that define TD: lip smacking, tongue thrusting, grimacing, and jerky limb movements.
The stronger a medication binds to dopamine receptors, and the longer you take it, the more likely this compensatory process becomes. That is why first-generation antipsychotics, which bind very tightly, cause TD at roughly double the rate of second-generation drugs, which tend to bind more loosely or also affect other brain pathways that partially offset the dopamine blockade.
Who Faces the Highest Risk
Not everyone on these medications develops TD, and your individual risk depends on several overlapping factors. Older adults are significantly more vulnerable, with symptoms appearing faster and after shorter courses of treatment. Women develop TD at higher rates than men. African Americans also face elevated risk, which may relate to genetic differences in how the liver processes these drugs.
Specific genes that control drug metabolism in the liver (the CYP2D6 enzyme family) play a measurable role. People who carry certain variants of these genes break down antipsychotics more slowly, leading to higher drug levels in the body and a greater chance of TD. These genetic differences are more common in some populations and partially explain why risk is not evenly distributed.
Other factors that increase your odds include having a mood disorder rather than schizophrenia, having a history of other movement-related side effects from these drugs (like restlessness or muscle stiffness early in treatment), intellectual disability, and any prior brain injury. Higher doses and longer treatment durations consistently raise risk across all groups.
How TD Is Detected
TD is assessed using a standardized exam called the AIMS (Abnormal Involuntary Movement Scale). During this brief evaluation, a clinician watches for involuntary movements in seven body regions, including the face, jaw, tongue, arms, legs, and trunk, rating each on a 0-to-4 severity scale. The exam takes only a few minutes and is meant to be repeated at regular intervals for anyone on a dopamine-blocking medication.
The challenge is that TD often starts subtly. Early signs might be slight tongue movements or minor lip twitching that you or your provider might not immediately notice. Because the condition can become permanent if not caught and addressed, regular screening matters. For most patients, the window where TD first becomes possible is around three months into treatment, but for older adults that window shrinks to as little as one month.
What Happens if You Stop the Medication
Stopping the offending drug does not guarantee TD will go away. In some cases, symptoms improve gradually over months or years after discontinuation. In others, the involuntary movements persist indefinitely, especially if the drug was taken for a long time before TD was recognized. Paradoxically, TD symptoms sometimes get temporarily worse right after stopping the medication, because the brain’s oversensitized dopamine receptors suddenly have access to more dopamine without the drug blocking them.
For people who cannot stop their antipsychotic because they need it for a serious psychiatric condition, switching to a lower-risk option like clozapine, quetiapine, or olanzapine is one common strategy. Two FDA-approved treatments specifically for TD (both are vesicular monoamine transporter inhibitors) can reduce the severity of involuntary movements, giving people a way to manage symptoms while continuing necessary psychiatric treatment.